Literature DB >> 34106577

DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma.

Amy E Chang, Marc R Radke, David B Zhen, Kelsey K Baker, Andrew L Coveler, Kit Man Wong, Venu G Pillarisetty, Deepti Reddi, Mary W Redman, Elizabeth Swisher, Elena Gabriela Chiorean.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34106577      PMCID: PMC8585585          DOI: 10.1097/MPA.0000000000001819

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


× No keyword cloud information.
  8 in total

1.  Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Authors:  Kathryn P Pennington; Tom Walsh; Maria I Harrell; Ming K Lee; Christopher C Pennil; Mara H Rendi; Anne Thornton; Barbara M Norquist; Silvia Casadei; Alexander S Nord; Kathy J Agnew; Colin C Pritchard; Sheena Scroggins; Rochelle L Garcia; Mary-Claire King; Elizabeth M Swisher
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

2.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.

Authors: 
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

3.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.

Authors:  Tom Walsh; Ming K Lee; Silvia Casadei; Anne M Thornton; Sunday M Stray; Christopher Pennil; Alex S Nord; Jessica B Mandell; Elizabeth M Swisher; Mary-Claire King
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Authors:  Elizabeth M Swisher; Kevin K Lin; Amit M Oza; Clare L Scott; Heidi Giordano; James Sun; Gottfried E Konecny; Robert L Coleman; Anna V Tinker; David M O'Malley; Rebecca S Kristeleit; Ling Ma; Katherine M Bell-McGuinn; James D Brenton; Janiel M Cragun; Ana Oaknin; Isabelle Ray-Coquard; Maria I Harrell; Elaina Mann; Scott H Kaufmann; Anne Floquet; Alexandra Leary; Thomas C Harding; Sandra Goble; Lara Maloney; Jeff Isaacson; Andrew R Allen; Lindsey Rolfe; Roman Yelensky; Mitch Raponi; Iain A McNeish
Journal:  Lancet Oncol       Date:  2016-11-29       Impact factor: 41.316

5.  Whole genomes redefine the mutational landscape of pancreatic cancer.

Authors:  Nicola Waddell; Marina Pajic; Ann-Marie Patch; David K Chang; Karin S Kassahn; Peter Bailey; Amber L Johns; David Miller; Katia Nones; Kelly Quek; Michael C J Quinn; Alan J Robertson; Muhammad Z H Fadlullah; Tim J C Bruxner; Angelika N Christ; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Craig Nourse; Ehsan Nourbakhsh; Shivangi Wani; Peter J Wilson; Emma Markham; Nicole Cloonan; Matthew J Anderson; J Lynn Fink; Oliver Holmes; Stephen H Kazakoff; Conrad Leonard; Felicity Newell; Barsha Poudel; Sarah Song; Darrin Taylor; Nick Waddell; Scott Wood; Qinying Xu; Jianmin Wu; Mark Pinese; Mark J Cowley; Hong C Lee; Marc D Jones; Adnan M Nagrial; Jeremy Humphris; Lorraine A Chantrill; Venessa Chin; Angela M Steinmann; Amanda Mawson; Emily S Humphrey; Emily K Colvin; Angela Chou; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Pettitt; Neil D Merrett; Christopher Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Nigel B Jamieson; Janet S Graham; Simone P Niclou; Rolf Bjerkvig; Robert Grützmann; Daniela Aust; Ralph H Hruban; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Massimo Falconi; Giuseppe Zamboni; Giampaolo Tortora; Margaret A Tempero; Anthony J Gill; James R Eshleman; Christian Pilarsky; Aldo Scarpa; Elizabeth A Musgrove; John V Pearson; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2015-02-26       Impact factor: 49.962

Review 6.  BRCAness revisited.

Authors:  Christopher J Lord; Alan Ashworth
Journal:  Nat Rev Cancer       Date:  2016-01-18       Impact factor: 60.716

7.  Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

Authors:  Eileen M O'Reilly; Jonathan W Lee; Mark Zalupski; Marinela Capanu; Jennifer Park; Talia Golan; Esther Tahover; Maeve A Lowery; Joanne F Chou; Vaibhav Sahai; Robin Brenner; Hedy L Kindler; Kenneth H Yu; Alice Zervoudakis; Shreya Vemuri; Zsofia K Stadler; Richard K G Do; Neesha Dhani; Alice P Chen; David P Kelsen
Journal:  J Clin Oncol       Date:  2020-01-24       Impact factor: 44.544

8.  Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.

Authors:  Talia Golan; Tal Sella; Eileen M O'Reilly; Matthew H G Katz; Ron Epelbaum; David P Kelsen; Ayelet Borgida; Hannah Maynard; Hedy Kindler; Eitan Friedmen; Milind Javle; Steven Gallinger
Journal:  Br J Cancer       Date:  2017-02-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.